Dotinor 0.5

Introduction
Gout is an inflammatory disease triggered by deposition of urate crystals secondary to longstanding hyperuricemia, and its management implies both the treatment of flares and management of hyperuricemia. Dotinor 0.5 is a selective urate reabsorption inhibitor (SURI), potently inhibits urate transporter 1 in the apical surface of renal proximal tubular cells, and has been approved for the treatment of gout and hyperuricemia.
Uses of Dotinor 0.5
For the treatment of gout and hyperuricemia.
Side effects of Dotinor 0.5
The most common side effects are gouty arthritis, limb discomfort (1% to less than 5%). (Loose stools, increased y-GTP, arthralgia, kidney stones, nephrocalcinosis, increased urinary y2 macroglobulin, increased blood creatinine, increased urine albumin/creatinine ratio, positive urine albumin) has been reported in less than 1% patients.
How to use Dotinor 0.5
_NAME_ administered orally once daily. The maintenance dose is usually 2 mg once a day and maximum dose should be 4 mg once a day.
How Dotinor 0.5 works
Dotinurad is a URAT1-selective urate reabsorption inhibitor that selectively inhibits URAT1 and inhibits urate reabsorption, thereby increasing urinary urate excretion and lowering serum urate levels. In addition, since it has weak inhibitory effects on ABCG2, OAT1 and OAT3 other than URAT143,44, it is expected to effectively lower serum uric acid levels without affecting uric acid secretion via these transporters. Thus, Dotinurad is a selective urate reabsorption inhibitor (SURI) that inhibits the reabsorption pathway mediated by URAT1 without inhibiting the uric acid secretion pathway mediated by ABCG2, OAT1 and OAT3 because of its high URAT1 selectivity.
What if you forget to take Dotinor 0.5?
Take the missed dose as soon as possible when you remember. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Never take two doses at once. Do not stop taking this medicine without your doctor’s advice.
Brief Description
Indication
It is indicated for the treatment of gout and hyperuricemia.
Administration
Dotinurad is administered orally. The maximum dose should be 4 mg once a day.
Adult Dose
The usual adult dosage is 0.5 mg of Dotinurad. In the early stages of treatment with urate-lowering drugs, gouty arthritis (gout attack) may be induced by a rapid decrease in blood uric acid levels. The dose should be gradually increased to 1 mg once a day after 2 weeks and 2 mg once a day after 6 weeks. Patients should be carefully monitored after the dose is increased. If you accidentally take too much, consult your doctor or pharmacist.
Child Dose
Not recommended for children.
Renal Dose
Consider treatment with other agents. Since this drug acts in the renal proximal tubule, its efficacy may be reduced depending on the degree of renal dysfunction. In particular, administration of this drug should be avoided in patients with oliguria or anuria, as its efficacy cannot be expected.
Contraindication
Dotinurad is contraindicated in patients with known hypersensitivity to the drug component.
Mode of Action
Dotinurad is a URAT1-selective urate reabsorption inhibitor that selectively inhibits URAT1 and inhibits urate reabsorption, thereby increasing urinary urate excretion and lowering serum urate levels. In addition, since it has weak inhibitory effects on ABCG2, OAT1 and OAT3 other than URAT143,44, it is expected to effectively lower serum uric acid levels without affecting uric acid secretion via these transporters. Thus, Dotinurad is a selective urate reabsorption inhibitor (SURI) that inhibits the reabsorption pathway mediated by URAT1 without inhibiting the uric acid secretion pathway mediated by ABCG2, OAT1 and OAT3 because of its high URAT1 selectivity.
Precaution
This drug is a uric acid-lowering drug and lowering the blood uric acid level at the onset of gouty arthritis (gouty attack) may exacerbate gouty arthritis (gouty attack). If gouty arthritis (gout attack) is observed before administration of this drug, administration of this drug should not be started until the symptoms subside. In addition, if gouty arthritis (gouty attack) occurs during administration of this drug, administration should be continued without changing the dose of this drug and colchicine, non-steroidal anti-inflammatory drugs, corticosteroids etc. may be administered depending on the symptoms. Use together.
Side Effect
Common side effects are: gouty arthritis, limb discomfort (1% to less than 5%). (Loose stools, increased y-GTP, arthralgia, kidney stones, nephrocalcinosis, increased urinary y2 macroglobulin, increased blood creatinine, increased urine albumin/creatinine ratio, positive urine albumin) has been reported in less than 1% patients.
Pregnancy Category Note
During pregnancy, Dotinurad should only be treated if the therapeutic benefits are judged to outweigh the risks.
Interaction
Pyrazinamide: The effect of this drug may be weakened. Pyrazinamide is known to suppress uric acid secretion in renal tubules and may antagonize the promotion of uric acid excretion by this drug. Salicylic acid preparations Aspirin: Salicylic acid preparations are known to suppress uric acid excretion and may antagonize the promotion of uric acid excretion by this drug.